Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
Clinical trial NCT05639114 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05639114
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-02
- Primary completion
- 2027-03-26
- Enrollment
- 436
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.